In this installment of Discourses in Dermatology, G. Michael Lewitt, MD, and Omar Noor, MD, FAAD, discuss bimekizumab, highlighting the remarkable patient outcomes observed in their clinical practices, how it stands out in a crowded treatment landscape, and its significant implications for psoriasis management.
A unique mechanism of action
Psoriasis intricately involves pathways like IL-23, IL-17, and TNF alpha, with specific immune cells perpetuating the inflammatory cascade. Recognizing the diverse isomers of IL-17, particularly IL-17A and IL-17F, forms the foundation of bimekizumab's approach. Unlike other medications that target solely IL-17A or the IL-17 receptor, bimekizumab is a pioneering treatment that addresses both IL-17A and F, presenting a novel mechanism of action.
Histological studies reveal elevated levels of IL-17F in psoriatic lesions, underscoring the significance of dual IL-17A and F inhibition. By precisely targeting these predominant isoforms, bimekizumab demonstrates enhanced efficacy in mitigating inflammation.
Patient success stories in clinical practice
Highlighting patient anecdotes, Dr Noor and Dr Lewitt underscore bimekizumab’s efficacy in challenging cases, from individuals resistant to conventional therapies to those weary from a carousel of treatments.
Both Dr Lewitt and Dr Noor share that their patients on bimekizumab showed significant clearance of psoriatic lesions by the time they returned for a 4-week follow-up and were able to rekindle a sense of optimism toward their treatment journeys after multiple failed responses to other therapies.
Counseling patients on adverse events
Addressing concerns about adverse events, Dr Noor advocates for comprehensive patient communication. Acknowledging the increased rates of anxiety and depression at baseline in patients with psoriasis, he emphasizes the importance of prioritizing discussions on emotional well-being alongside treatment efficacy. He encourages colleagues to address any relevant medical history of major depressive disorders or antidepressant use to ensure bimekizumab is the right fit for a given patient.
An approach to monitoring
In terms of monitoring, Dr Noor adheres to standard biologics protocols, conducting CBC, CMP, and QuantiFERON-TB Gold tests at baseline along with an acute hepatitis panel to exclude the possibility of hepatitis B in patients. Dr Noor’s personal recommendation is to follow up with another CMP or LFT at 6 to 12 weeks, and if levels remain stable, repeat yearly going forward.
A convenient dosing schedule
The recommended dosing schedule for bimekizumab is administration of 320 mg (two 160-mg injections) at weeks 0, 4, 8, 12, and 16, then every 8 weeks thereafter.
Notably, this dosing schedule is unique to bimekizumab, offering an appealing option to patients who are concerned about the frequency of medication administration. This approach not only enhances patient compliance but also accommodates individual needs, particularly in the case of overweight patients who may need to remain on an every-4-week dosing schedule.
Standing out in a crowded landscape
Drs Lewitt and Noor conclude their discussion by reflecting on the crowded psoriasis treatment landscape. Despite the many options available, they acknowledge that persistent unmet needs remain. They remark that bimekizumab stands out by effectively addressing these needs through its distinct mechanism of action, rapid efficacy, and favorable safety profile, allowing them to maintain the commitment to prioritizing patient well-being amid the evolving landscape of psoriasis therapeutics.
In the first DermInsider - A Virtual Grand Rounds Series session of the year, join leading experts Dr. Bhutani and Dr. Serota for a dynamic deep dive into one of the most exciting frontiers in psoriatic disease management. Dr. Del Rosso moderates this 45-minute activity that explores the rapidly emerging role of glucagon-like peptide-1 receptor agonists (GLP-1RAs) and their potential impact beyond metabolic disease. Don't miss out on this opportunity to catch up on breakthrough insights and emerging evidence on this hot topic!“We have some really interesting data on the horizon that’s going to hopefully help more providers feel confident about using [GLP-1] medications in conjunction with their psoriasis medications that they are used to using.” – Tina Bhutani, MD MASBest of FC25: GLP-1RAs in Psoriasis – Catching Up on The ScienceThis activity is supported by an educational grant from Lilly.
Got a few minutes? Join our expert faculty for their rapid-fire tips on getting started with GLP-1 receptor agonists for patients with psoriasis and obesity.“When we are treating patients with obesity and psoriasis in weight management, really focus on the health gains. It’s not about what people are losing, it’s about what they are gaining in this process.” – Angela Fitch, MDPlease visit the “Educational Resources” page to access the handouts developed by faculty on GLP's in psoriatic disease mentioned in this activity.This activity is supported by an educational grant from Lilly.
In this 20-minute Seminar in Depth from the 2025 Fall Clinical Dermatology Conference, the faculty explore what differentiates TYK2 inhibitors from traditional JAK inhibitors, as well as how to identify patients with psoriasis who may benefit from oral small molecule therapy.“When thinking about a medication, you need to take a number of things into consideration: location of disease, disease severity, and age. Age plays a big role when I think about what medication I’m going to choose for a patient – Are they of child-bearing age? Are they young and they live in group housing or a dorm?” – Benjamin Lockshin, MDFC25: Encapsulating Progress With New and Emerging TYK2 Inhibitors for Psoriasis: An Online ActivityThis activity is supported by an educational grant from Bristol Myers Squibb.